SMARCA4 and neoplasm: Inhibition of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4, could potently inhibit tumor growth of PCa and synergize with the AR antagonist enzalutamide for better tumor control, even inducing disease remission in CRPC models, suggesting that SWI/SNF subunits serve as potential therapeutic targets in PCa [18–20].